We are harnessing the biology of human aging to develop new therapies for cardiometabolic diseases

Find out more

Harnessing aging to transform health

Obesity and other cardiometabolic diseases are among the most prevalent and pressing health challenges of our time.

Age is a critical risk factor.

NLRP3:
targeting chronic inflammation

BGE-102 is a potential best-in-class NLRP3 inhibitor. It has the potential to block the chronic inflammation linked to cardiometabolic and retinal diseases.

We anticipate QUELL CV Phase 2 results in the second half of 2026 and QUELL DME Phase 2 results in the second half of 2027.

Learn more about NLRP3

APJ: exercise mimetic for obesity

Apelin is a molecule that is secreted in response to exercise. Agonism of the apelin receptor APJ has the potential to double weight loss and fully restore body composition on an incretin background in preclinical models of obesity.

IND submission anticipated by 2026 year end.

Learn more about APJ

Discovery platform

Our human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease.

Our pipeline programs target key pathways that drive metabolic aging based on novel insights from our platform.